Ontogeny of protection of neonatal mice from lethal herpes simplex virus infection by human leukocytes, antiviral antibody, and recombinant alpha-interferon.
We have studied the peripheral blood leukocytes from human infants in an assay involving the protection of neonatal mice from herpes simplex virus (HSV) infection by human antibody, interferon, and leukocytes. Recombinant DNA alpha-interferon (IFLrA), antibody, and Ficoll-Hypaque-purified mononuclear cells (MC) from human adults administered intraperitoneally protected neonatal mice from a lethal HSV challenge 1 day later (73.6% survival). MC obtained from human infants less than 130 days old in combination with IFLrA and antibody afforded no protection (15.2% survival; p less than 0.0005 compared to survival with adults' MC). MC from infants over 130 days protected the neonatal mice [60% survival; not significantly different from survival using adult cells, but significantly (p less than 0.0005) different than survival using MC from younger infants]. The ontogeny of MC protection parallels the clinical development of resistance of infants to HSV infection.
D000818:Animals; D000831:Animals, Newborn / Q000276:immunology*; D000914:Antibodies, Viral / Q000276:immunology*; D004274:DNA, Recombinant; D004195:Disease Models, Animal; D006561:Herpes Simplex / Q000276:immunology* / Q000401:mortality / Q000517:prevention & control; D006801:Humans; D007370:Interferon Type I / Q000276:immunology*; D007962:Leukocytes / Q000276:immunology*; D051379:Mice; D008810:Mice, Inbred C57BL; D012044:Regression Analysis
D000914:Antibodies, Viral; D004274:DNA, Recombinant; D007370:Interferon Type I